Join
Live feed
·
PRReleasevia Quantisnow
Incyte Corp. logo
Syndax Pharmaceuticals Inc. logo

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

ByQuantisnow·Wall Street's wire, on your screen.
INCY· Incyte Corp.SNDX· Syndax Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INCY (Incyte Corp.), SNDX (Syndax Pharmaceuticals Inc.) and more on Quantisnow.

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases | Quantisnow